C-Rad AB (publ) (CRAD_B) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to our Q1 presentation. We started the year with a solid quarter in a wait and see market. As most of you know, CRUD is active within radiation therapy and more than half of all cancer patients undergo radiation therapy at some point of the treatment. And our focus at C-Rad is the end-to-end surface-guided workflow from CT room to treatment room, where our surface-guided radiation technology, or SGRT, supports that the dose reaches the tumor and not the healthy tissue of the patient. But let me first zoom out and remind you of C-Rad's long-term strategy and priorities. Also, as many of you know, We have announced our medium term financial targets, which I will come back to later on in the presentation. So first, I will take you through our progress for Q1. Let me take you through the slide left to right. So first, I will start to the left with the market. We, CWAD, have a global reach and expanding step by step to grow our sales. And in line with our ambition to grow in the US, we had US retrofit wins on Varian Linux also for this quarter. And that is a good step in the right direction to strengthen our position in the US. With our focus on EMEA, we are pleased that order intake was up 15% in the quarter. In addition, we also held an EMEA distributor training in the quarter. In APAC, we received a large multi-hospital order in Taiwan. Secondly, we have a market-leading patient-centric portfolio, and we invest in innovation. At the important trade show Estro, we launched new patient-centric functionality with focus on the clinical workflow, and that we have developed in close collaboration with strategic customers. At Estro, we also presented our new Catalyst Plus Light offering for the first time. And this offering is designed for clinics that are in the begi...